Direct-to-Drug Screening Tool Allows for Precision Medicine in Multiple Myeloma
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
Multiple Myeloma
Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Ixazomib Found Effective as a Maintenance Therapy in Patients With Newly Diagnosed MM Who Are Ineligible for Transplant
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
All Oral Proteasome Inhibitor-Containing Regimen in Transplant-Ineligible Multiple Myeloma
Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Novel Triple Therapy With First-in-Class Selinexor Improves Outcomes in Multiple Myeloma
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
KRd Fails to Improve Outcomes Compared With VRd in Newly Diagnosed MM
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
-
Loading...
-
Loading...
Next post in ASCO 2020
